Compendium of Cancer Genome Aberrations

HAEM5:High grade B-cell lymphoma with 11q aberrations: Difference between revisions

[checked revision][checked revision]
← Older editNewer edit →
VisualWikitext
No edit summary
Undo revision 14873 by Bailey.Glen (talk)
Tag: Undo
Line 1: Line 1:
{{DISPLAYTITLE:High grade B-cell lymphoma with 11q aberrations}}
{{DISPLAYTITLE:High grade B-cell lymphoma with 11q aberrations}}
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]
[[HAEM5:Table_of_Contents|Haematolymphoid Tumours (5th ed.)]]


{{Under Construction}}
{{Under Construction}}
Line 7: Line 7:
}}</blockquote>
}}</blockquote>


<span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples); to add (or move) a row or column to a table, click nearby within the table and select the > symbol that appears to be given options. Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span>
<span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span>


==Primary Author(s)*==
==Primary Author(s)*==
Line 27: Line 27:
==Definition / Description of Disease==
==Definition / Description of Disease==


Put your text here <span style="color:#0070C0">(''Instructions: Brief description of approximately one paragraph - include disease context relative to other WHO classification categories, diagnostic criteria if applicable, and differential diagnosis if applicable. Other classifications can be referenced for comparison.'') </span>
Put your text here <span style="color:#0070C0">(''Instructions: Brief description of approximately one paragraph - include disease context relative to other WHO classification categories referring to the specific WHO book pages, diagnostic criteria if applicable, and differential diagnosis if applicable'') </span>


==Synonyms / Terminology==
==Synonyms / Terminology==
Line 74: Line 74:
==Immunophenotype==
==Immunophenotype==


Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table. Do not delete table.'') </span>
Put your text here and fill in the table <span style="color:#0070C0">(''Instruction: Can include references in the table'') </span>


{| class="wikitable sortable"
{| class="wikitable sortable"
Line 80: Line 80:
!Finding!!Marker
!Finding!!Marker
|-
|-
|Positive (universal)||<span class="blue-text">EXAMPLE:</span> CD1
|Positive (universal)||EXAMPLE CD1
|-
|-
|Positive (subset)||<span class="blue-text">EXAMPLE:</span> CD2
|Positive (subset)||EXAMPLE CD2
|-
|-
|Negative (universal)||<span class="blue-text">EXAMPLE:</span> CD3
|Negative (universal)||EXAMPLE CD3
|-
|-
|Negative (subset)||<span class="blue-text">EXAMPLE:</span> CD4
|Negative (subset)||EXAMPLE CD4
|}
|}




<blockquote class='blockedit'>{{Box-round|title=HAEM5 Conversion Notes|The content below was from the previous version of the page. Please incorporate above.}}
<blockquote class='blockedit'>{{Box-round|title=v4:Immunophenotype|The content below was from the previous version of the page. Please incorporate above.}}
{| class="wikitable sortable"
{| class="wikitable sortable"
|-
|-
Retrieved from "https://test.ccga.io/index.php/HAEM5:High_grade_B-cell_lymphoma_with_11q_aberrations"